X
Calliditas pushing on with kidney disease drug after IPO success
https://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/
biotech IPO
Circassia a cautionary tale for UK biotech, says Grainger
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
Cancer biotech BeyondSpring hit by weak IPO
Hoping for $100m, biotech raises under $3.5 million on stock market
Jounce set to make first biotech IPO of 2017
Massachusetts-based company will test the waters for biotech sector
